Kumar Sambamurti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2158879/publications.pdf

Version: 2024-02-01

		44444	36203
116	10,922	50	101
papers	citations	h-index	g-index

122	122	122	13022
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development of early biomarkers of Alzheimer's disease: A precision medicine perspective. , 2024, , 511-525.		0
2	Mechanistic Insights Into Gut Microbiome Dysbiosis-Mediated Neuroimmune Dysregulation and Protein Misfolding and Clearance in the Pathogenesis of Chronic Neurodegenerative Disorders. Frontiers in Neuroscience, 2022, 16, 836605.	1.4	17
3	Sex-Specific Regulation of Î²-Secretase: A Novel Estrogen Response Element (ERE)-Dependent Mechanism in Alzheimer's Disease. Journal of Neuroscience, 2022, 42, 1154-1165.	1.7	6
4	Indoles as essential mediators in the gut-brain axis. Their role in Alzheimer's disease. Neurobiology of Disease, 2021, 156, 105403.	2.1	39
5	Rivastigmine modifies the Î±-secretase pathway and potentially early Alzheimerâ€™s disease. Translational Psychiatry, 2020, 10, 47.	2.4	44
6	Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 37-45.	1.8	29
7	Melatonin Treatment Enhances AÎ² Lymphatic Clearance in a Transgenic Mouse Model of Amyloidosis. Current Alzheimer Research, 2018, 15, 637-642.	0.7	38
8	When figures and data contradict text: MiR346 is apparently reduced in breast cancer tissue, contrary to claims by a paper's author. Gene, 2017, 635, 46-47.	1.0	0
9	Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimerâ€™s Disease. Current Alzheimer Research, 2015, 12, 32-46.	0.7	255
10	P4-156: Methionine restriction leads to AÎ² reduction and neuroprotection: Implications in Alzheimer's disease pathogenesis and prevention. , 2015, 11, P838-P839.		2
11	Resolution of inflammation is altered in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 40.	0.4	208
12	Beta-Amyloid Precursor Protein (Î²APP) Processing in Alzheimerâ€™s Disease (AD) and Age-Related Macular Degeneration (AMD). Molecular Neurobiology, 2015, 52, 533-544.	1.9	65
13	Preface. Turkish Journal of Medical Sciences, 2015, 45, i-ii.	0.4	0
14	Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. , 2014, 10, S62-S75.		64
15	Evidence for lymphatic AÎ² clearance in Alzheimer's transgenic mice. Neurobiology of Disease, 2014, 71, 215-219.	2.1	48
16	Amyloidâ€Î² precursor protein synthesis inhibitors for Alzheimer's disease treatment. Annals of Neurology, 2014, 76, 629-630.	2.8	5
17	Evidence of a Novel Mechanism for Partial Î³-Secretase Inhibition Induced Paradoxical Increase in Secreted Amyloid Î² Protein. PLoS ONE, 2014, 9, e91531.	1.1	19
18	Major Carboxyl Terminal Fragments Generated by Î³-Secretase Processing of the Alzheimer Amyloid Precursor Are 50 and 51 Amino Acids Long. American Journal of Geriatric Psychiatry, 2013, 21, 474-483.	0.6	12

#	Article	IF	Citations
19	Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, α -Synuclein Synthesis, Interleukin-1β Release, and Cholinergic Action.. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2013, 12, 117-128.	1.1	23
20	Applying Epigenetics to Alzheimerâ€™s Disease via the Latent Earlyâ€“life Associated Regulation (LEARn) Model. Current Alzheimer Research, 2012, 9, 589-599.	0.7	53
21	The Psen1â€Ł166P â€knockâ€in mutation leads to amyloid deposition in human wildâ€type amyloid precursor protein YAC transgenic mice. FASEB Journal, 2012, 26, 2899-2910.	0.2	13
22	Drug Discovery for Neurodegenerative Diseases: Challenges and Novel Biochemical Targets. Journal of Alzheimer's Disease, 2011, 24, 1-2.	1.2	13
23	Vitamin D3-Enriched Diet Correlates with a Decrease of Amyloid Plaques in the Brain of AÎ²PP Transgenic Mice. Journal of Alzheimer's Disease, 2011, 25, 295-307.	1.2	123
24	Targets for AD treatment: conflicting messages from Î³-secretase inhibitors. Journal of Neurochemistry, 2011, 117, 359-374.	2.1	59
25	Human Retinal Pigment Epithelium Cells as Functional Models for the RPE In Vivo. , 2011, 52, 8614.		210
26	Differential Accumulation of Secreted AÎ²PP Metabolites in Ocular Fluids1. Journal of Alzheimer's Disease, 2010, 20, 1243-1253.	1.2	52
27	GLP-1 Receptor Stimulation Reduces Amyloid-Î² Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 1205-1219.	1.2	273
28	Neuronutrition and Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 1123-1139.	1.2	90
29	Higher Incidence of Mild Cognitive Impairment in Familial Hypercholesterolemia. American Journal of Medicine, 2010, 123, 267-274.	0.6	102
30	A Novel Endogenous Indole Protects Rodent Mitochondria and Extends Rotifer Lifespan. PLoS ONE, 2010, 5, e10206.	1.1	38
31	Pigment Epithelium-derived Factor Maintains Retinal Pigment Epithelium Function by Inhibiting Vascular Endothelial Growth Factor-R2 Signaling through Î³-Secretase. Journal of Biological Chemistry, 2009, 284, 30177-30186.	1.6	62
32	GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1285-1290.	3.3	483
33	Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Experimental Neurology, 2009, 216, 278-289.	2.0	115
34	Challenges Associated with Metal Chelation Therapy in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 457-468.	1.2	139
35	Frontiers in the pathogenesis of Alzheimer's disease. Indian Journal of Psychiatry, 2009, 51 Suppl 1, S56-60.	0.4	3
36	Early-life events may trigger biochemical pathways for Alzheimerâ€™s disease: the â€œLEARnâ€•model. Biogerontology, 2008, 9, 375-379.	2.0	58

#	Article	IF	Citations
37	High cholesterolâ€induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. Journal of Neurochemistry, 2008, 106, 475-485.	2.1	304
38	Role of DNA dynamics in Alzheimer's disease. Brain Research Reviews, 2008, 58, 136-148.	9.1	28
39	Geranylgeranyl pyrophosphate stimulates Î³â€secretase to increase the generation of AÎ² and APPâ€CTFÎ³. FASEB Journal, 2008, 22, 47-54.	0.2	54
40	An Increase in Aβ42 in the Prefrontal Cortex is Associated with a Reversal-Learning Impairment in Alzheimers Disease Model Tg2576 APPsw Mice. Current Alzheimer Research, 2008, 5, 385-391.	0.7	29
41	Beta-Secretase: Structure, Function, and Evolution. CNS and Neurological Disorders - Drug Targets, 2008, 7, 278-294.	0.8	93
42	Effects of a Saturated Fat and High Cholesterol Diet on Memory and Hippocampal Morphology in the Middle-Aged Rat. Journal of Alzheimer's Disease, 2008, 14, 133-145.	1.2	250
43	Value in Development of a TAPIR-Like Mouse Monoclonal Antibody to AÎ². Journal of Alzheimer's Disease, 2008, 14, 175-177.	1.2	3
44	Dissociation Between the Potent Î²-Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine. , 2008, , 445-462.		2
45	The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-Î² Peptide Levels in Cell Culture and Mice. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 386-396.	1.3	122
46	TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets. Current Alzheimer Research, 2007, 4, 378-385.	0.7	178
47	Age-dependent loss of NGF signaling in the rat basal forebrain is due to disrupted MAPK activation. Neuroscience Letters, 2007, 413, 110-114.	1.0	41
48	Insulysin Cleaves the APP Cytoplasmic Fragment at Multiple Sites. Neurochemical Research, 2007, 32, 2225-2234.	1.6	21
49	Gamma Secretase. , 2007, , 1-10.		0
50	Beta Secretase. , 2007, , 1-8.		0
51	Secretases. , 2007, , 1-5.		0
52	Increased App Expression in a Mouse Model of Down's Syndrome Disrupts NGF Transport and Causes Cholinergic Neuron Degeneration. Neuron, 2006, 51, 29-42.	3.8	488
53	Neurine, an acetylcholine autolysis product, elevates secreted amyloid-Î² protein precursor and amyloid-Î² peptide levels, and lowers neuronal cell viability in culture: A role in Alzheimer's disease?. Journal of Alzheimer's Disease, 2006, 10, 9-16.	1.2	10
54	Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid Î² peptide levels. Neurobiology of Disease, 2006, 22, 651-656.	2.1	108

#	Article	IF	Citations
55	A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis. Current Alzheimer Research, 2006, 3, 81-90.	0.7	67
56	Genotoxicity in Alzheimers Disease: Role of Amyloid. Current Alzheimer Research, 2006, 3, 365-375.	0.7	10
57	Taking Down the Unindicted Co-Conspirators of Amyloid β-Peptidemediated Neuronal Death: Shared Gene Regulation of BACE1 and APP Genes Interacting with CREB, Fe65 and YY1 Transcription Factors. Current Alzheimer Research, 2006, 3, 475-483.	0.7	32
58	Identification of Novel Small Molecule Inhibitors of Amyloid Precursor Protein Synthesis as a Route to Lower Alzheimer's Disease Amyloid-Î² Peptide. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 855-862.	1.3	39
59	An Overview of Phenserine Tartrate, A Novel Acetylcholinesterase Inhibitor for the Treatment of Alzheimers Disease. Current Alzheimer Research, 2005, 2, 281-290.	0.7	118
60	Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer Â-amyloid peptide in rodent. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17213-17218.	3.3	629
61	Commentary: â€œCeramide and cholesterol: Possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?â€• by Claudio Costantini, Rekha M.K. Kolasani, Luigi Puglielli. , 2005, 1, 53-54.		0
62	Differential Expression of Cholesterol Hydroxylases in Alzheimer's Disease. Journal of Biological Chemistry, 2004, 279, 34674-34681.	1.6	238
63	Functional characterization of the 5â€² flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression. FASEB Journal, 2004, 18, 1037-1039.	0.2	58
64	Amyloid Precursor Protein Compartmentalization Restricts Î²-Amyloid Production: Therapeutic Targets Based on BACE Compartmentalization. Journal of Molecular Neuroscience, 2004, 24, 137-144.	1.1	40
65	New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF-Â Inhibitors, and GLP-1 Receptor Agonists. Annals of the New York Academy of Sciences, 2004, 1035, 290-315.	1.8	91
66	Gene structure and organization of the human Î²â€‹secretase (BACE) promoter. FASEB Journal, 2004, 18, 1034-1036.	0.2	171
67	Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimerâ€™s disease. Neurobiology of Aging, 2004, 25, 651-660.	1.5	113
68	Rationale for the Development of Cholinesterase Inhibitors as Anti- Alzheimer Agents. Current Pharmaceutical Design, 2004, 10, 3111-3119.	0.9	86
69	Cholesterol and Alzheimers Disease: Clinical and Experimental Models Suggest Interactions of Different Genetic, Dietary and Environmental Risk Factors. Current Drug Targets, 2004, 5, 517-528.	1.0	57
70	Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. Acta Neurobiologiae Experimentalis, 2004, 64, 1-9.	0.4	33
71	Î²-Secretase Processing of the Alzheimer's Amyloid Protein Precursor (APP). Journal of Molecular Neuroscience, 2003, 20, 233-240.	1.1	81
72	Glucagon-like peptide-1 decreases endogenous amyloid-Î² peptide (AÎ²) levels and protects hippocampal neurons from death induced by AÎ² and iron. Journal of Neuroscience Research, 2003, 72, 603-612.	1.3	309

#	Article	IF	Citations
73	17Î²-Estradiol Reduces Plasma AÎ²40 for HRT-NaÃ¯ve Postmenopausal Women With Alzheimer Disease: A Preliminary Study. American Journal of Geriatric Psychiatry, 2003, 11, 239-244.	0.6	2
74	APH1, PEN2, and Nicastrin increase AÎ² levels and Î³-secretase activity. Biochemical and Biophysical Research Communications, 2003, 305, 502-509.	1.0	44
75	Addendum â€œAPH1, PEN2, and Nicastrin increase AÎ² levels and Î³-secretase activityâ€•[Biochem. Biophys. Res. Commun. 305 (2003) 502â€“509]. Biochemical and Biophysical Research Communications, 2003, 307, 756.	1.0	0
76	Alzheimer's Disease Î²-Amyloid Peptide Is Increased in Mice Deficient in Endothelin-converting Enzyme. Journal of Biological Chemistry, 2003, 278, 2081-2084.	1.6	228
77	Amyloid-Â peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6221-6226.	3.3	279
78	A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease. Current Drug Targets, 2003, 4, 97-112.	1.0	198
79	17beta-estradiol reduces plasma Abeta40 for HRT-naÃ¯ve postmenopausal women with Alzheimer disease: a preliminary study. American Journal of Geriatric Psychiatry, 2003, 11, 239-44.	0.6	25
80	Nicotine lowers the secretion of the Alzheimer's amyloid Î²-protein precursor that contains amyloid Î²-peptide in rat. Journal of Alzheimer's Disease, 2002, 4, 405-415.	1.2	50
81	Targeting APP metabolism for the treatment of Alzheimer's disease. Drug Development Research, 2002, 56, 211-227.	1.4	15
82	Current drug targets for Alzheimer's disease treatment. Drug Development Research, 2002, 56, 267-281.	1.4	181
83	Lipid rafts play an important role in AÎ² biogenesis by regulating the Î²-secretase pathway. Journal of Molecular Neuroscience, 2002, 19, 31-35.	1.1	77
84	The Role of the Carboxylâ€Terminal Fragments of Amyloid Precursor Protein in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2002, 973, 334-339.	1.8	13
85	Butyrylcholinesterase: An Important New Target in Alzheimer's Disease Therapy. International Psychogeriatrics, 2002, 14, 77-91.	0.6	351
86	Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's Disease. NeuroMolecular Medicine, 2002, 1, 1-32.	1.8	181
87	Characterization of Recombinant, Soluble Î²-Secretase from an Insect Cell Expression System. Molecular Pharmacology, 2001, 59, 619-626.	1.0	29
88	Phenserine regulates translation of Â-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7605-7610.	3.3	204
89	Convertases other than furin cleave Î²â€secretase to its mature form. FASEB Journal, 2001, 15, 1810-1812.	0.2	33
90	Reduction of AÎ² accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidylinositol kinase inhibitor wortmannin. FASEB Journal, 2001, 15, 16-18.	0.2	50

#	Article	IF	Citations
91	A Novel Î³-Secretase Assay Based on Detection of the Putative C-terminal Fragment-Î³ of Amyloid Î² Protein Precursor. Journal of Biological Chemistry, 2001, 276, 481-487.	1.6	135
92	Cellâ€free assays for Î³â€secretase activity. FASEB Journal, 2000, 14, 2383-2386.	0.2	108
93	Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model. Neurobiology of Disease, 2000, 7, 321-331.	2.1	964
94	Glycosylphosphatidylinositol-anchored Proteins Play an Important Role in the Biogenesis of the Alzheimer's Amyloid Î²-Protein. Journal of Biological Chemistry, 1999, 274, 26810-26814.	1.6	50
95	Antisense-Induced Reduction of Presenilin 1 Expression Selectively Increases the Production of Amyloid beta42 in Transfected Cells. Journal of Neurochemistry, 1999, 73, 2383-2388.	2.1	47
96	Glycosylphosphatidylinositol-anchor intermediates associate with Triton-insoluble membranes in subcellular compartments that include the endoplasmic reticulum. Biochemical Journal, 1999, 343, 627.	1.7	14
97	The secretion of amyloid Î²-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Molecular Brain Research, 1998, 62, 131-140.	2.5	85
98	Release of Nontransmembrane Full-Length Alzheimer's Amyloid Precursor Protein from the Lumenar Surface of Chromaffin Granule Membranesâ€. Biochemistry, 1998, 37, 1274-1282.	1.2	29
99	ERAB Contains a Putative Noncleavable Signal Peptide. Biochemical and Biophysical Research Communications, 1998, 249, 546-549.	1.0	8
100	The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells. Life Sciences, 1997, 61, 1985-1992.	2.0	9
101	The heat shock/oxidative stress connection. Molecular and Chemical Neuropathology, 1996, 28, 21-34.	1.0	31
102	Evidence that secretase cleavage of cell surface Alzheimer amyloid precursor occurs after normal endocytic internalization. Journal of Neuroscience Research, 1995, 40, 694-706.	1.3	60
103	Heat-shock induces abnormalities in the cellular distribution of amyloid precursor protein (APP) and APP fusion proteins. Neuroscience Letters, 1995, 192, 105-108.	1.0	10
104	Study of the phorbol ester effect on Alzheimer amyloid precursor processing: Sequence requirements and involvement of a Cholera toxin sensitive protein. Journal of Neuroscience Research, 1994, 38, 81-90.	1.3	38
105	Cellular Processing and Proteoglycan Nature of Amyloid Precursor Proteinsa. Annals of the New York Academy of Sciences, 1993, 695, 132-138.	1.8	6
106	The Alzheimer's Amyloid Precursor Is Cleaved Intracellularly in the Trans-Golgi Network or in a Post-Golgi Compartment. Annals of the New York Academy of Sciences, 1992, 674, 118-128.	1.8	26
107	Evidence for intracellular cleavage of the Alzheimer's amyloid precursor in PC12 cells. Journal of Neuroscience Research, 1992, 33, 319-329.	1.3	149
108	The genesis of the senile plaque. Further evidence in support of its neuronal origin. American Journal of Pathology, 1992, 141, 1151-9.	1.9	20

#	Article	IF	Citations
109	Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Molecular Brain Research, 1991, 10, 173-178.	2.5	99
110	Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells. Neuroscience Letters, 1991, 128, 126-128.	1.0	217
111	Human retina D2 receptor cDNAs have multiple polyadenylation sites and differ from a pituitary clone at the 5â€² non-coding region. Nucleic Acids Research, 1990, 18, 1299-1299.	6.5	9
112	Mutagenesis by aflatoxin in M13 DNA: Base-substitution mechanisms and the origin of strand bias. Molecular Genetics and Genomics, 1989, 217, 20-25.	2.4	16
113	Mechanisms of mutagenesis by chloroacetaldehyde.. Genetics, 1989, 121, 213-222.	1.2	29
114	Mechanisms of mutagenesis by a bulky DNA lesion at the guanine N7 position.. Genetics, 1988, 120, 863-873.	1.2	68
115	DNA replication-blocking properties of adducts formed by aflatoxin B1-2,3-dichloride and aflatoxin B1-2,3-oxide. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1987, 179, 89-101.	0.4	30
116	Sequence context effects in DNA replication blocks induced by aflatoxin B1.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 3096-3100.	3.3	34